Keith Daniels Kaufman MD
Diabetes, Lipid Metabolism
Vice President, Project Leadership & Management, Merck Research Laboratories
Join to View Full Profile
PO Box 2000RY34-A4063Rahway, NJ 07065
Dr. Kaufman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Fellowship, Endocrinology, Diabetes, and Metabolism, 1987 - 1989- University of California San Francisco School of MedicineClass of 1983
Certifications & Licensure
CA State Medical License 1986 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Publications & Presentations
PubMed
- 3 citationsCorifollitropin Alfa Combined With Human Chorionic Gonadotropin in Adolescent Boys With Hypogonadotropic Hypogonadism.R Ravi Shankar, Suneri Shah, Hee-Koung Joeng, Geraldine Mendizabal, Julia R DiBello
The Journal of Clinical Endocrinology and Metabolism. 2022-06-16 - 16 citationsEfficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulinMuhammad Yazid Jalaludin, Asma Deeb, Philip Zeitler, Raymundo Garcia, Ron S. Newfield
Pediatric Diabetes. 2021-11-14 - 16 citationsA randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetesR. Ravi Shankar, Philip Zeitler, Asma Deeb, Muhammad Yazid Jalaludin, Raymundo Garcia
Pediatric Diabetes. 2021-11-14
Journal Articles
- A Randomized Clinical Trial of the Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in Patients with Type 2 Diabetes Mellitus and Mild Renal Insufficienc...Keith Kaufman, MD, Diabetes, Obesity and Metabolism
Press Mentions
Court Let Merck Hide Secrets About Baldness Drug’s RisksSeptember 11th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
